EcoDrugPlus

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSLBEG00000019047
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLBEG00000006961
Gene Symbol: RAMP1
1 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLBEG00000013941
Gene Symbol: RAMP1
3 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLBEG00000026548
Gene Symbol: RAMP1
2 Cross references
191 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSLBEG00000017019
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSLBEG00000012001
Gene Symbol: LOC109984951
3 Cross references
206 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSLBEG00000013070
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Renin-Like

Ensembl ID : ENSLBEG00000009527
Gene Symbol: LOC109980999
3 Cross references
219 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSLBEG00000012461
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSLBEG00000007629
Gene Symbol: LOC109986633
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSLBEG00000027453
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSLBEG00000007276
Gene Symbol: LOC109998695
2 Cross references
380 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).